Abdel-Azim, H., Quigg, T., Kapoor, N., Chi, Y.-Y., Higham, C., Keating, A., … Pulsipher, M. (2025). High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701). In Blood (Vol. 146, pp. 163–163). American Society of Hematology. https://doi.org/10.1182/blood-2025-163

Abdel-Azim, Hisham, Troy Quigg, Neena Kapoor, Yueh-Yun Chi, Christine Higham, Amy Keating, Vanessa Fabrizio, et al. “High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701).” In Blood, 146:163–163. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-163.

Abdel-Azim H, Quigg T, Kapoor N, Chi Y-Y, Higham C, Keating A, et al. High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701). In: Blood. American Society of Hematology; 2025. p. 163–163.

Abdel-Azim, Hisham, et al. “High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701).” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 163–163. Crossref, doi:10.1182/blood-2025-163.

Abdel-Azim H, Quigg T, Kapoor N, Chi Y-Y, Higham C, Keating A, Fabrizio V, Skiles J, Shenoy S, Khazal S, Gardenswartz A, Madden L, Milner J, Phelan R, Caywood E, Duffner U, Fish J, Galvez Silva J, Gillio A, Hanna R, Huo J, Lalefar N, Mahadeo K, McNerney K, Dolan JG, Salzberg D, Stefanski H, Pulsipher M. High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701). Blood. American Society of Hematology; 2025. p. 163–163.